Search Results
Your search for all items matches 34943 pages
Showing 2651 - 2700ASCO and Ontario Health Publish New Recommendations for Systemic Therapy in SCLC
A newly published guideline update from ASCO and Ontario Health provides evidence-based recommendations on the use of systemic therapy for small cell lung cancer (SCLC).1 Recommendations cover where novel agents fit in the treatment landscape, the management of disease in older patients with...
Expert Point of View: Christopher J. Sweeney, MBBS
Invited discussant of the PSMAfore trial, Christopher J. Sweeney, MBBS, Director of the South Australian Immunogenics Cancer Institute, University of Adelaide, Australia, congratulated the authors for a well-powered, controlled phase III trial. “The study showed clear documentation of...
Improving Cancer Control in a Changing World
On October 16 and 17, 2023, the Union for International Cancer Control (UICC) welcomed more than 350 attendees from over 75 countries to its World Cancer Leaders’ Summit in Long Beach, California, to discuss some of the most challenging issues facing patients with cancer worldwide. The theme of...
LuPSMA: Another Treatment Option for Metastatic Castration-Resistant Prostate Cancer
The use of lutetium-177–labeled PSMA-617 (LuPSMA) improved radiographic progression–free survival by 57% in men with metastatic castration-resistant prostate cancer who experienced disease progression on an androgen receptor (AR) pathway inhibitor compared with changing to a new AR pathway...
NIH Immunotherapy Pioneer Steven A. Rosenberg, MD, PhD, Awarded Nation’s Highest Honor for Technology and Innovation
Immunotherapy pioneer Steven A. Rosenberg, MD, PhD, has been awarded the National Medal of Technology and Innovation by President Biden. It is the nation’s highest honor for technological achievement. Dr. Rosenberg is Chief of the Surgery Branch at the Center for Cancer Research at the National...
Neoadjuvant/Adjuvant Pembrolizumab in Resectable NSCLC
On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC).1 Supporting Efficacy Data Approval was based ...
I Don’t Want Cancer to Define Me
Except for a series of unexplained multiple broken bones and inexplicable excruciating pain in my right hip and leg, I had no other hallmarks of multiple myeloma when I was diagnosed with the disease at age 48 in 2014. My blood test values were all normal, and I didn’t have anemia or kidney damage. ...
Overall Survival With LuPSMA vs Cabazitaxel in Previously Treated Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, overall survival results from the Australian phase II TheraP trial showed no difference with lutetium-177–labeled PSMA-617 (LuPSMA) vs cabazitaxel in patients with metastatic castration-resistant prostate cancer and...
EGFR-Mutated Advanced NSCLC: CNS Efficacy With Combination of Osimertinib and Chemotherapy
In a subgroup analysis from the phase III FLAURA2 trial reported in the Journal of Clinical Oncology, Pasi A. Jänne, MD, PhD, and colleagues found the combination of osimertinib and chemotherapy improved central nervous system (CNS) efficacy vs osimertinib alone in the first-line treatment of...
Implementation of Updated WHO Screening Guidelines Could Reduce Cervical Cancer Mortality by Over 50% in Lower-Income Countries
Investigators have found that implementing the updated World Health Organization (WHO) screening guidelines may effectively reduce the cervical cancer mortality rate in patients residing in low- and middle-income countries, according to two recent studies published by Simms et al and Hall et al in...
New Findings Challenge Widely Accepted Beliefs About the Relative Efficacy of Opioids in Treating Cancer Pain
Investigators have uncovered concerningly large gaps in evidence regarding the true benefits of opioids for pain relief in patients with cancer, according to a novel study published by Shaheed et al in CA: A Cancer Journal for Clinicians. The new findings could challenge the commonly held view that ...
Imetelstat for RBC Transfusion Independence in Lower-Risk Myelodysplastic Syndromes
As reported in The Lancet by Uwe Platzbecker, MD, and colleagues, the phase III IMerge trial has shown improved red blood cell transfusion independence with imetelstat, a competitive telomerase inhibitor, vs placebo in RBC transfusion-dependent patients with lower-risk myelodysplastic syndromes who ...
International Collaborative Research Efforts in Cardio-oncology: Focus on Basic and Translational Science
Translational research is a key ingredient in guiding both genetic and pharmacologic cardioprotective approaches in patients being treated for cancer, according to international experts from the International Cardio-Oncology Society and the Global Cardio-Oncology Symposium (GCOS) committee. Fadi N. ...
Melanoma in Younger Individuals
This is Part 4 of Evolving Skin Cancer Management, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Pauline Funchain, Alison Vidimos, and Lisa Zaba review the case of a 32-year-old patient who recently gave birth to her first...
Early Detection and Management in Merkel Cell Carcinoma
This is Part 3 of Evolving Skin Cancer Management, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Pauline Funchain, Alison Vidimos, and Lisa Zaba discuss the importance of early detection and multidisciplinary treatment of...
Multidisciplinary Management in Cutaneous Squamous Cell Carcinoma
This is Part 2 of Evolving Skin Cancer Management, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Pauline Funchain, Alison Vidimos, and Lisa Zaba review how the multidisciplinary team comes together to treat cutaneous squamous...
Nonsurgical Approaches to Basal Cell Carcinoma
This is Part 1 of Evolving Skin Cancer Management, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Pauline Funchain, Alison Vidimos, and Lisa Zaba discuss nonsurgical treatment options for basal cell carcinoma. The patient is a...
Expert Point of View: Bonny Morris, PhD, RN, MSPH
Invited discussant Bonny Morris, PhD, RN, MSPH, of the American Cancer Society, underscored the use of precision medicine education, literacy, and language-concordant educational tools, as well as effective interventions for food insecurity, to improve cancer health equity in underserved rural...
Community Program Cuts Treatment Delays in Half for Minority and Low-Income Patients
A program aimed at improving access to high-quality cancer care has significantly increased adherence to cancer treatment among minority and low-income communities, according to data presented at the 2023 ASCO Quality Care Symposium.1 The introduction of the ALCANCE-PLUS program in Monterey County, ...
Expert Point of View: Bonny Morris, PhD, RN, MSPH
Invited discussant Bonny Morris, PhD, RN, MSPH, of the American Cancer Society, underscored the significance of the study’s findings for the veteran community. “There are more than 50,000 veterans diagnosed with cancer each year, with the most common cancers being prostate, lung, and colorectal,”...
The Power of Patient Advocacy: 10-Year Study Reveals Increased Survival Rates With Enhanced Advance Care Planning
A decade-long journey toward improving end-of-life care for patients with advanced cancer has demonstrated positive effects on survival, health-care use, and cost of care, according to data presented at the 2023 ASCO Quality Care Symposium.1 Post hoc analysis of an advance care planning...
Allogeneic Hematopoietic Stem Cell Transplantation for Dendritic Cell Neoplasm Subtype
Allogeneic hematopoietic stem cell transplantation can safely and effectively treat patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially during first remission, according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 4988). Results of the...
Overcoming BPDCN: Tagraxofusp Sets New Landmark in Patient Survival
A novel first-in-class therapy may help to redefine survival expectations for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 547). Results of a European named-patient program study showed...
Age, Race, and Sex Found to Impact Survival Rates in Patients With BPDCN
Age, race, and sex have significant implications for survival rates of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 5185). Findings from the largest U.S. population–based BPDCN study...
All Adult Oncologists Are Geriatric Oncologists
The data developed over the past few years have overwhelmingly favored geriatric assessment as part of the routine care for older patients with cancer. It has become the standard of care. ASCO has recently published a Practical Geriatric Assessment to aid in the implementation of this vital...
Expert Point of View: Susan Faye Dent, MD
In a joint ASCO/ICOS (International Cardio-Oncology Society) session presented at the 2023 Global Cardio-Oncology Summit, Dr. Anita Arnold and Dr. Krishnan Bhaskaran discussed the importance of understanding the impact of cancer therapy on the cardiovascular health of women. Medical oncologist...
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
At the 2023 Global Cardio-Oncology Summit in Madrid, in a joint session with ASCO and the International Cardio-Oncology Society, Anita Arnold, DO, FACC, MBA, Director, Noninvasive Cardiology, and Director of Cardio-Oncology, Lee Memorial Health Systems, Fort Myers, Florida, discussed the...
Is Prediabetes Linked to Cardiovascular and Kidney Diseases in Adult Survivors of Childhood Cancer?
In a study reported in the Journal of Clinical Oncology, Dixon et al found that adult survivors of childhood cancers with prediabetes were at an increased risk of developing cardiovascular events and chronic kidney disease. The study involved data from 3,529 ≥ 5-year survivors of childhood cancer...
5-Year Outcomes of the IDEA Trial: Omission of Radiotherapy After Breast-Conserving Surgery for Low-Risk Patients
As reported in the Journal of Clinical Oncology by Reshma Jagsi, MD, DPhil, and colleagues, a 5-year analysis of the IDEA trial showed a very low rate of recurrence with the omission of radiotherapy after breast-conserving surgery in patients at low clinical and genomic risk for disease ...
Advanced NSCLC: Adding Canakinumab to First-Line Chemoimmunotherapy
As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK...
Expert Point of View: Valentina Guarneri, MD
Invited discussant of the HER2CLIMB-02 trial, Valentina Guarneri, MD, of Padeva Istituto Oncologica Veneto, Italy, hailed these results as important, especially for patients with HER2-positive breast cancer and brain metastases. However, she noted, “HER2CLIMB-02 is not likely to challenge the...
HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with unresectable, locally advanced or metastatic HER2-positive breast cancer, according to...
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
As reported in The New England Journal of Medicine by Kathleen N. Moore, MD, and colleagues, the phase III MIRASOL trial has shown improved progression-free and overall survival with mirvetuximab soravtansine-gynx vs chemotherapy in previously treated patients with folate receptor–alpha...
Psilocybin-Assisted Therapy May Reduce Depressive Symptoms in Patients With Cancer
Researchers have uncovered that psilocybin-assisted therapy may be safe and effective in patients with cancer and comorbid major depressive disorder, according to two novel studies published by Agrawal et al and Beaussant et al in Cancer. Background Psilocybin is a hallucinogenic chemical found in...
Lung Nodule Program May Help Detect Cancer in Patients Age-Ineligible for Lung Cancer Screening
Researchers have found that adopting a Lung Nodule Program may increase early lung cancer detection in patients who are not eligible for lung cancer screening under existing age-eligibility criteria, according to a recent study published by Liao et al in the Journal of Thoracic Oncology. ...
Childhood Cancer Survivors: Risk of Second Cancer and Heart Disease
In a French study of more than 7,000 childhood cancer survivors published by Charrier et al in JACC: CardioOncology, researchers reported that the occurrence of a second malignant neoplasm among these survivors seemed to be associated with an increased risk of cardiac disease occurrence and risk at ...
DNA Mutational Profiling in Patients With Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Innocenti et al, analysis of DNA mutational profiling in the phase III CALGB (Alliance)/SWOG 80405 trial of patients with metastatic colorectal cancer treated with bevacizumab or cetuximab with chemotherapy showed differences in outcome associated...
HPV ctDNA Detection After Chemoradiation in Patients With Cervical Cancer
In a study reported in the Journal of Clinical Oncology, Han et al found that persistent human papillomavirus (HPV) circulating tumor DNA (ctDNA) after chemoradiation was associated with poorer outcomes in patients with cervical cancer. Patients at high risk of poorer outcomes could also be...
Adding Immune Checkpoint Inhibitors to Perioperative Treatment for Solid Tumors: Associated Toxicity?
In a systematic review and meta-analysis reported in The Lancet Oncology, Fujiwara et al found that the addition of immune checkpoint inhibitors to perioperative therapy in patients with solid tumors was associated with an increased risk of grade 3 and 4 treatment-related adverse events and adverse ...
W. Kimryn Rathmell, MD, PhD, Begins Work as 17th Director of the NCI
On December 18, W. Kimryn Rathmell, MD, PhD, began her work as the 17th Director of the National Cancer Institute (NCI). Dr. Rathmell was selected by President Biden to succeed Monica M. Bertagnolli, MD, FACS, FASCO, who left NCI to become the Director of the National Institutes of Health (NIH) on...
GLP-1 Receptor Agonists May Reduce Risk of Colorectal Cancer in Patients With High BMI and Diabetes
Glucagon-like peptide 1 (GLP-1) receptor agonists may be effective at reducing the risk of colorectal cancer in patients with a higher body mass index (BMI) and diabetes, according to a recent study published by Wang et al in JAMA Oncology. Background Obesity is a chronic health condition that...
William G. Wierda, MD, PhD, on Use of Pirtobrutinib for Richter Transformation: Updated Efficacy and Safety Results
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the phase I/II BRUIN study, which shows encouraging response and overall survival in patients with Richter transformation. Although this condition remains a challenging diagnosis, pirtobrutinib...
Mikkael A. Sekeres, MD, on Therapies for Hematologic Cancers: Is More or Less Better?
Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781,...
Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy
Darren Denjay Pan, MD, of Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses his findings on risk assessment of CAR T-cell therapy for patients with multiple myeloma. Higher fibrinogen and ferritin values at baseline were associated with inferior overall survival...
Hope S. Rugo, MD, on Advanced Breast Cancer: Patient-Reported Outcomes From the CAPItello-291 Trial
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient-reported outcomes from the phase III CAPItello-291 study; the trial centered on adding capivasertib to fulvestrant in patients with aromatase inhibitor–resistant,...
Eleftherios P. Mamounas, MD, on Locoregional Irradiation, Axillary Lymph Node Involvement, and Conversion to Negative Nodes
Eleftherios P. Mamounas, MD, of Orlando Health Cancer Institute, discusses primary outcomes from the NRG Oncology/NSABP B-51/RTOG 1304 study of locoregional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant ...
Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes
Nadia Harbeck, MD, PhD, of LMU University Hospital and Ludwig Maximilian University of Munich, and Daniel Kates-Harbeck, of the West German Study Group and an MD Candidate at Ludwig Maximilian University of Munich, discuss a learning-based neural network developed by Mr. Kates-Harbeck to predict...
Luca Gianni, MD, on Locally Advanced, HER2-Positive Breast Cancer: New Data on Neoadjuvant Therapy and Atezolizumab
Luca Gianni, MD, of Milan’s Fondazione Michelangelo, discusses findings from the APTneo Michelangelo trial, which showed that adding atezolizumab to chemotherapy and trastuzumab plus pertuzumab did not significantly increase the rate of pathologic complete response (pCR) in women with HER2-positive ...
Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial
Oleg Gluz, MD, of the West German Study Group and Breast Center Niederrhein, discusses the impact of age and ovarian function suppression in response to preoperative endocrine treatment for both pre- and postmenopausal patients with early-stage breast cancer. He describes ways in which the outcome...
Pieter Sonneveld, MD, PhD, on Newly Diagnosed Multiple Myeloma: Phase III Findings on Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone
Pieter Sonneveld, MD, PhD, of the Netherland’s Erasmus MC Cancer Institute, discusses primary results from the Perseus trial, showing that for patients with newly diagnosed multiple myeloma who are eligible for transplantation, the combination of daratumumab plus bortezomib, lenalidomide, and...
